Show simple item record

dc.contributor.authorFillmore, Nathanael
dc.contributor.authorBell, Steven
dc.contributor.authorShen, Ciyue
dc.contributor.authorNguyen, Vinh
dc.contributor.authorLa, Jennifer
dc.contributor.authorDubreuil, Maureen
dc.contributor.authorStrymish, Judith
dc.contributor.authorBrophy, Mary
dc.contributor.authorMehta, Gautam
dc.contributor.authorWu, Hao
dc.contributor.authorLieberman, Judy
dc.contributor.authorDo, Nhan
dc.contributor.authorSander, Chris
dc.date.accessioned2021-11-05T00:30:28Z
dc.date.available2021-11-05T00:30:28Z
dc.date.issued2021
dc.identifier.issn1932-6203
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/330303
dc.description.abstractEffective, low-cost therapeutics are needed to prevent and treat COVID-19. Severe COVID-19 disease is linked to excessive inflammation. Disulfiram is an approved oral drug used to treat alcohol use disorder that is a potent anti-inflammatory agent and an inhibitor of the viral proteases. We investigated the potential effects of disulfiram on SARS-CoV-2 infection and disease severity in an observational study using a large database of clinical records from the national US Veterans Affairs healthcare system. A multivariable Cox regression adjusted for demographic information and diagnosis of alcohol use disorder revealed a reduced risk of SARS-CoV-2 infection with disulfiram use at a hazard ratio of 0.66 (34% lower risk, 95% confidence interval 24-43%). There were no COVID-19 related deaths among the 188 SARS-CoV-2 positive patients treated with disulfiram, in contrast to 5-6 statistically expected deaths based on the untreated population (P = 0.03). Our epidemiological results suggest that disulfiram may contribute to the reduced incidence and severity of COVID-19. These results support carefully planned clinical trials to assess the potential therapeutic effects of disulfiram in COVID-19.
dc.languageeng
dc.publisherPublic Library of Science (PLoS)
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleDisulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.
dc.typeArticle
prism.issueIdentifier10
prism.publicationDate2021
prism.publicationNamePLoS One
prism.startingPagee0259061
prism.volume16
dc.identifier.doi10.17863/CAM.77747
dcterms.dateAccepted2021-10-11
rioxxterms.versionofrecord10.1371/journal.pone.0259061
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021
dc.contributor.orcidFillmore, Nathanael [0000-0002-8058-3423]
dc.contributor.orcidBell, Steven [0000-0001-6774-3149]
dc.contributor.orcidShen, Ciyue [0000-0002-5416-2481]
dc.contributor.orcidLa, Jennifer [0000-0003-2266-0221]
dc.contributor.orcidMehta, Gautam [0000-0002-5696-359X]
dc.contributor.orcidWu, Hao [0000-0002-7281-8579]
dc.contributor.orcidLieberman, Judy [0000-0002-6200-4715]
dc.contributor.orcidDo, Nhan [0000-0001-6868-7011]
dc.contributor.orcidSander, Chris [0000-0001-6059-6270]
dc.identifier.eissn1932-6203
rioxxterms.typeJournal Article/Review
cam.issuedOnline2021-10-28


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International